Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/4031
Title: | The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males | Authors: | Sargentini-Maier, Maria Laura Rolan, Paul Connell, John Tytgat, Dominique JACOBS, Tom Pigeolet, Etienne Riethuisen, Jean-Michel Stockis, Armel |
Issue Date: | 2007 | Publisher: | BLACKWELL PUBLISHING | Source: | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 63(6). p. 680-688 | Abstract: | Aims The objective of the study was to evaluate the pharmacokinetics (and how they are affected by food), CNS pharmacodynamics and the adverse event profile of brivaracetam after single increasing doses. Methods Healthy males (n = 27, divided into three alternating panels of nine subjects) received two different single oral doses of brivaracetam (10-1400 mg) and one dose of placebo during three periods of a randomized, double-blind, placebo-controlled study. The effect of food on its pharmacokinetics was assessed using a standard two-way crossover design in a further eight subjects who received two single oral doses of brivaracetam (150 mg) in the fasting state and after a high fat meal. Results Adverse events, none of which were serious, were mostly CNS-related and included somnolence, dizziness, and decreased attention, alertness, and motor control. Their incidence, severity and duration were dose-related. The maximum tolerated dose was established to be 1000 mg. Severe somnolence lasting 1 day occurred in one subject following 1400 mg. Brivaracetam was rapidly absorbed under fasting conditions, with a median t(max) of approximately 1 h. C-max was dose-proportional from 10 to1400 mg, whereas AUC deviated from dose linearity above 600 mg. A high-fat meal had no effect on AUC (point estimate 0.99, 90%CI: 0.92-1.07) but delayed t(max) (3 h) and decreased C-max (point estimate 0.72, 90%CI: 0.66-0.79). Conclusions Brivaracetam was well tolerated after increasing single doses that represent up to several times the expected therapeutic dose. Brivaracetam was found to have desirable pharmacokinetic properties. The most common adverse events were somnolence and dizziness. | Notes: | UCB Bioprod SA, Res & Dev, B-1420 Braine lAlleud, Belgium. Medeval Ltd, Manchester, Lancs, England. Univ Adelaide, Adelaide, SA 5005, Australia. Univ Hasselt, Dept Stat, Diepenbeek, Belgium.Sargentini-Maier, ML, UCB Bioprod SA, Res & Dev, Chemin Foriest, B-1420 Braine lAlleud, Belgium.laura.maier@ucb-group.com | Keywords: | antiepileptics; brivaracetam; pharmacodynamics; pharmacokinetics; ucb 34714 | Document URI: | http://hdl.handle.net/1942/4031 | ISSN: | 0306-5251 | e-ISSN: | 1365-2125 | ISI #: | 000246576800006 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2008 |
Appears in Collections: | Research publications |
Show full item record
WEB OF SCIENCETM
Citations
97
checked on May 2, 2024
Page view(s)
78
checked on Jun 14, 2023
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.